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Abstract 
Background: Human leukocyte antigen (HLA) surface proteins are directly involved in idiosyncratic adverse drug 
reactions. Herein, we present a structure-based analysis of the common HLA-B*57:01 variant known to be responsible 
for several HLA-linked adverse effects such as the abacavir hypersensitivity syndrome.
Methods: First, we analyzed three X-ray crystal structures involving the HLA-B*57:01 protein variant, the anti-HIV 
drug abacavir, and different co-binding peptides present in the antigen-binding cleft. We superimposed the three 
complexes and showed that abacavir had no significant conformational variation whatever the co-binding peptide. 
Second, we self-docked abacavir in the HLA-B*57:01 antigen binding cleft with and without peptide using Glide. 
Third, we docked a small test set of 13 drugs with known ADRs and suspected HLA associations.
Results: In the presence of an endogenous co-binding peptide, we found a significant stabilization (~2 kcal/mol) 
of the docking scores and identified several modified abacavir–peptide interactions indicating that the peptide 
does play a role in stabilizing the HLA–abacavir complex. Next, our model was used to dock a test set of 13 drugs at 
HLA-B*57:01 and measured their predicted binding affinities. Drug-specific interactions were observed at the antigen-
binding cleft and we were able to discriminate the compounds with known HLA-B*57:01 liability from inactives.
Conclusions:  Overall, our study highlights the relevance of molecular docking for evaluating and analyzing complex 
HLA–drug interactions. This is particularly important for virtual drug screening over thousands of HLA variants as other 
experimental techniques (e.g., in vitro HTS) and computational approaches (e.g., molecular dynamics) are more time 
consuming and expensive to conduct. As the attention for drugs’ HLA liability is on the rise, we believe this work par-
ticipates in encouraging the use of molecular modeling for reliably studying and predicting HLA–drug interactions. 
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Background
Certain patients develop harmful adverse drug reactions 
(ADRs) after taking a medication [1]. Unfortunately, 
these undesired reactions to a drug or its metabolite(s) 
can potentially be serious and even life threatening. 
According to the FDA Adverse Event Reporting System 
(FAERS), over one million cases of ADRs were observed 
in 2014 and this number is steadily increasing as report-
ing systems become more accessible to physicians [2]. 
There are two main classifications of ADRs: Predictable 
ADRs occur due to the pharmacological activity of a drug 
or its metabolites, whereas idiosyncratic ADRs are pri-
marily observed as an immune system response [3, 4]. 
The major biological pathway capable of triggering such 
idiosyncratic ADRs is activated by a drug’s direct binding 
with human leukocyte antigen (HLA) protein variants 
[4–6].
Class I HLA variants form protein complexes consti-
tuted by two main polypeptides and a short self-peptide 
[7]. As the self-peptide is usually 8–10 residues long, 
the two polypeptides (approximately 270 residues) form 
the binding cleft and are also bound to β2-microglobulin 
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(β2-m), approximately 90–100 residues [7]. Further-
more, the binding cleft can be subdivided into three 
α-subdomains that consists of two alpha helical regions 
(α1 and α2) and a third region (α3) that helps in stabiliz-
ing the HLA-protein to the cell surface (in addition to the 
stabilization from β2-m) [7]. A groove forms between the 
α1 and α2 subdomains that consists of alpha-helical walls 
and a β-pleated floor where “self” peptides can bind [7, 
8]. In case of infection, pathogens (e.g., viral peptides) 
can bind to HLA instead of the self-peptides and ignite 
an immune reaction. Indeed, HLA serves as signaling 
proteins for T cell activation through a variety of pro-
posed mechanisms (e.g., hapten concept, super antigen 
interactions, pharmacological interactions, altered rep-
ertoire) [4, 9]. Overall, the general signaling mechanism 
involves an antigen (or a drug in the case of ADR) and/
or a peptide (endogenous or exogenous) directly bind-
ing to the antigen cleft of the HLA, resulting in a signal 
presentation to T-cell receptors triggering a response of 
the immune system (Fig. 1). As of today, over 15,000 dif-
ferent HLA-variants have been identified in humans and 
reported in the IMGT/HLA database [10]. Focusing on 
ADRs, each variant has hypothetically the potential to 
form a HLA–drug complex with selective binding inter-
actions. Therefore, the number of possible HLA–drug 
combinations is enormous and explains why HLA-medi-
ated ADRs are extremely hard to predict and, obviously, 
rarely observed during clinical trials due to the small 
number of participants. Furthermore, prioritizing HLA-
variants to target for drug screening can be extremely 
challenging due to the varying frequency of HLA-variant 
by ethnicity [11].
Even though the vast majority of HLA variants are rare, 
there are several well-known cases of HLA-mediated 
ADRs. For instance, carbamazepine (brand name Tegre-
tol) is used for the treatment of seizures, but patients 
carrying the HLA-B*15:02 variant [12, 13] have an 
increased likelihood to suffer from the Steven-Johnson 
Syndrome (SJS) or toxic epidermal necrolysis (TEN) 
[14]. Another well-established example is flucloxacillin 
(Floxapen), a beta-lactam anti-microbial, that can cause 
typical drug-induced liver injury (DILI) in patients pos-
sessing the HLA-B*57:01 variant [15]. Additionally, 
HLA-B*57:01 is responsible for abacavir hypersensitivity 
syndrome (AHS) which is a severe, life-threatening ADR 
occurring in patients prescribed abacavir for treating 
HIV infection [16].
Clearly, the ability of a drug to bind with a given HLA-
variant plays a significant role in determining whether 
that compound or its metabolite(s) may potentially trig-
ger ADRs in a given subpopulation carrying that particu-
lar HLA variant. Therefore, computational approaches 
able to forecast such HLA–drug molecular interactions 
reliably could have serious implications in preventing 
ADRs and thus potentially contribute to the develop-
ment of precision medicine. Using in silico techniques 
to predict drugs’ liabilities has now become a common, 
reliable enough, and cheap enough screening approach, 
especially for toxicity and ADRs evaluations [17–30]. 
Typically, forecasting potential ADR involves analyzing 
the chemical space with chemical similarity techniques 
[17–20]. Liu et  al. recently used a 2D structural alert—
based screening for chemical similarity to forecast ADR 
[17], while Vilar et  al. employed a 3D pharmacophore-
based similarity search in order to predict ADR [18]. 
Alternatively, quantitative-structure activity relationship 
(QSAR) models have been developed in order to forecast 
drug-induced SJS [19] or DILI [20]. New methods can 
use a systems chemical biology approach in order to pre-
dict drug hepatoxicity through the integration of chemi-
cal and biological data [21, 22].
However, there are very few molecular modeling stud-
ies in the literature attempting to analyze and predict 
the molecular interactions between drugs and HLA 
variants. For instance, Luo et al. [23] modeled the inter-
actions between various HLA variants and some endog-
enous peptides using a network analysis approach, but 
the authors did not examine potential drug binding 
events. Recently, Paul et  al. developed two approaches 
for predicting HLA-Class I and -Class II epitopes using 
TepiTool [31] and the Immune Epitope Database and 
Analysis Resonance [32]. Another group developed a 
very useful, online database compiling all of the known 
HLA–drug interactions resulting in ADRs (HLADR, 
http://pgx.fudan.edu.cn/hladr/); however, this database 
is based solely on measured odds ratios (ORs) obtained 
from existing literature [24]. Recently, Yang et  al. [25] 
conducted a preliminary molecular docking study on 
abacavir using AutoDock Vina, but little details were 
Fig. 1 Scheme representation of altered-repertoire binding and 
signaling mechanism of antigen/drug, HLA-receptor, and peptide for 
T-cell activation
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discussed regarding the actual binding mode of the drug. 
In a proof-of-concept study, we used molecular docking 
to predict the binding modes of clozapine with several 
HLA-variants and explore some possible clozapine–
HLA interactions [26]. Clozapine (Clozaril) is an efficient 
antipsychotic that may result in agranulocytosis/granulo-
cytosis when a patient has HLA-DQB1 or specific HLA-B 
variants [26, 27].
Alfirevic et  al. [28] attempted to establish a HLA-
typed DNA archive that could be used to map DILI 
events between class I and II HLAs using distance trees. 
Recently, Schotland et  al. [29] attempted to data-mine 
FAERS reports for SJS/TEN associations with HLA-vari-
ants using the Molecular Analysis of Side Effects (MASE) 
approach. Additionally, Schotland et  al. performed a 
homology docking model of carbamazepine (and sev-
eral other drugs) at the HLA-B*15:02 variant [29]. This 
homology model was developed from work previously 
performed by Wei et al. [30]. Both research groups were 
able to successfully verify the importance of the ARG62 
residue for carbamazepine binding at B*15:02 [29, 30]. 
Furthermore, using this same homology model Zhou 
et al. conducted a molecular dynamic simulation explor-
ing the T-cell signaling mechanism of bonded carbamaz-
epine with HLA-B*15:02 [33]. Overall, the literature on 
the computational modeling of HLA–drug complexes is 
limited but definitely emerging.
Recently, Metushi et  al. conducted a virtual screening 
of the ZINC database in order to attempt HLA-B*57:01 
liable chemicals [34]. The ZINC database contains over 
35 million commercially available compounds [35]. 
Using concatenated FP2 and FP4 structural finger-
prints, Metushi et  al. conducted a 2D-similarity search 
of abacavir on 3.5 million compounds from the ZINC 
database followed by a 3D-similarity search using phar-
macophoric features of abacavir [34]. From this initial 
screening, 54 compounds were identified and selected for 
molecular docking using the X-ray crystal 3UPR. Next, 
Metushi et  al. identified seven compounds that were 
tested for HLA-B*57:01 affinity from which acyclovir was 
identified as a potential candidate [34]. But, when acyclo-
vir was subjected to a CD8+ T-cell response assay [36], 
it was determined that acyclovir did not induce a CD8+ 
T-cell response [34]. This study by Metushi et  al. [34] 
represents a full in silico to in vitro screening for HLA-
B*57:01 liable compounds from ZINC.
Developing molecular docking protocols that effec-
tively identify hits can be a challenging undertaking, 
especially when it comes to the preparation of complex 
proteins, such as HLA [37]. Moreover, when molecular 
docking was conducted in published studies involving 
HLA proteins, it was not specified if a co-binding peptide 
was present or absent. As such, we believe that it is of the 
utmost importance that a thorough analysis of molecular 
docking targeting the HLA-B*57:01 variant be conducted 
in order to properly identify the limitations of this molec-
ular modeling technique for forecasting a drug’s likeli-
hood to bind a HLA variant and thus potentially cause a 
HLA-mediated ADR.
In this study, we are employing structure-based dock-
ing [38] to predict and analyze the molecular interac-
tions between different drugs and the relatively common 
HLA-B*57:01 variant. First, we decided to focus on 
abacavir (brand name Ziagen) due to the availability of 
three X-ray crystals (PDB: 3VRI, 3VRJ, and 3UPR) [16, 
39]. These X-ray crystals include abacavir and unique co-
binding peptides bound in the antigen-binding cleft of 
HLA-B*57:01 (Fig. 2) [16, 39]. We tested whether molec-
ular docking would be able to obtain native-like peptide–
abacavir–HLA complexes. Second, we considered 13 
other drugs with known or putative HLA-binding asso-
ciations resulting in ADR events. We docked them in the 
antigen-binding cleft of HLA-B*57:01 in presence and 
absence of an endogenous peptide and critically analyzed 
their docking scores and binding modes.
Overall, this study underlines the relevance of employ-
ing molecular docking for analyzing and predicting 
HLA–drug interactions. Due to the large number of 
HLA-alleles [10] and their varying frequency of occur-
rence by ethnicity [11], the ability to forecast idiosyncratic 
ADRs is extremely difficult and thus the development of 
HLA–drug specific virtual screening procedures could 
become a key component of future precision medicine 
protocols. Importantly, the goal of this research was to 
test molecular docking as a computationally inexpensive 
virtual screening approach for the reliable prediction of 
critical drug–HLA-B*57:01 interactions triggering ADR 
events. As such, molecular dynamic simulations were not 
considered in this study, especially when considering the 
screening of drugs towards thousands of HLA variants.
Methods
Dataset
Three X-ray crystals including abacavir bound to the 
antigen-binding cleft of HLA-B*57:01 with an endog-
enous peptide were downloaded from the Protein Data 
Bank: 3VRI (resolution 1.6 Å, peptide P1, Fig.  2), 3VRJ 
(resolution 1.9 Å, peptide P2), and 3UPR (resolution 2.0 
Å, peptide P3) [16, 39]. The three crystal structures are 
highly similar and consist of bound abacavir covered by 
a differing endogenous peptide. In the case of 3VRI and 
3VRJ, there are three distinct chains constructing the 
protein, chain A (275 residues for both crystals), chain 
B (100 and 99 residues, respectively), and chain C cor-
responding to the peptides P1 and P2, respectively (10 
residues). Crystal 3UPR is a dimer with matching chains 
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A and C (275 residues each), an interlinking chain B and 
D connecting chains A and C (99 residues), and chains P 
and Q corresponding to the peptide P3 (9 residues). The 
binding pocket is located on chain A for 3VRI, 3VRJ, and 
3UPR (as well as chain C for 3UPR because it is a dimer).
In order to identify any significant differences between 
the binding sites of 3VRI, 3VRJ, and 3UPR, we analyzed 
the overall protein structure, ligand conformation, and 
co-binding peptides in several different ways. First, a 
general all-atom alignment was performed between the 
protein structures as implemented in the Schrodinger 
Suite [40]. In general, a measured RMSD value can be 
used to determine structural similarity between closely 
related proteins (as is the case with our three crystals of 
the HLA-B*57:01 protein) [41]. Next, a peptide backbone 
alignment was performed on the three co-binding pep-
tides present in addition to superimposition of bound 
abacavir from the three crystals. Additionally, overlay 
similarity scores were calculated between the three struc-
tures for the protein, co-binding peptides, and bound 
abacavir using Discovery Studio [42]. Finally, a binding 
site-specific alignment was performed using residues 
within 5 Å of bound abacavir.
Next, the physical chemical characteristics of the 
binding pocket were explored using SiteMap [43, 44]. 
SiteMap characterizes the possible binding sites of a pro-
tein by analyzing several physical chemical properties, 
such as size, volume, exposure to solvent, hydrophobic 
and hydrophilic space, and H-donor/-acceptor ability 
[43, 44]. Using these descriptors, two scores are gener-
ated: Site Score (Sscore) and Drugability Score (Dscore). 
A binding pocket that is likely to bind a ligand will have 
an Sscore greater than 0.8 and a Dscore greater than 
0.83 [43, 44]. Using the default SiteMap parameters (6 
Å buffer region, a minimum of 15 site points, restrictive 
hydrophobicity, and a standard grid), the HLA-B*57:01 
binding pockets were analyzed under three conditions. 
First, the binding pocket was analyzed in the presence 
of the co-binding peptide using abacavir as the reference 
ligand. Second, the ligand binding environment was ana-
lyzed in the absence of co-binding peptide with abacavir 
as the reference compound. Third, the peptide was used 
as the reference ligand to map the binding pocket. Ana-
lyzing the peptide binding pocket of HLA-B*57:01 under 
these three conditions afforded a detailed analysis of 
how the ligand and peptide could impact the binding 
environment.
Abacavir’s binding mode with HLA-B*57:01 occurs 
through an altered repertoire mechanism. The altered 
repertoire binding mechanism occurs when an antigen 
binds non-covalently to the HLA active site and then, an 
endogenous or exogenous peptide binds non-covalently 
across the active site [4, 9, 16, 39]. This prevents the anti-
gen from exiting the binding cleft, while also serving as a 
signaling trigger to T-cells resulting in an immune system 
response. As such, the model developed for this study 
used an altered repertoire binding mechanism. A cartoon 
schematic of this mechanism is provided in Fig. 1.
The test set of HLA-liable drugs considered in this 
study is as follows: abacavir (Zaigen) [16, 39, 45–47], 
allopurinol (Zyloprim) [48, 49], atorvastatin (Lipitor), 
carbamezapine (Tegretol) [12, 13, 29, 30, 50], ciprofloxa-
cin (Cipro), clozapine (Clozril) [26, 27, 51, 52], fenofi-
brate (Triocor), flucloxacillin (Floxapen) [15], methyldopa 
Fig. 2 Structure of the HLA-B*57:01 variant in complex with abacavir (represented in CPK) and peptide P1 (colored in yellow)—PDB code = 3VRI
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(Aldomet), minocycline (Minocin), pazopanib (Votrient) 
[53], sertraline (Zoloft), simvastatin (Zocor), and ticlo-
pidine (Ticlid) [54]. It is worth noting that the drugs 
abacavir, flucloxacillin, and pazopanib are all HLA-
B*57:01 actives, while the rest of the compounds are 
believed to be inactive towards this particular HLA vari-
ant. The set is provided in Table 1 with their respective 
indications, ADR event, and HLA-association. The set 
was structurally preprocessed using LigPrep from the 
Schrodinger Suite [37]. Prior to docking, the therapeutic 
classes of the test set of ligands were explored in addition 
to measuring compound similarities. The well-known 
MACCS key structural fingerprints were employed to 
compute the pairwise 2D-similarity for the entire test set 
of compounds [55]. Similarity scores were determined by 
measuring the Tanimoto coefficients which can be deter-
mined using the following equation,
Where TC is the tanimoto similarity score, bC are the 
common bits for both compounds, b1 are the bits from 
molecule one, and b2 are the bits from molecule two [56].
Molecular docking
Prior to the modeling, we conducted a 3D alignment of 
3VRI, 3VRJ, and 3UPR in order to evaluate any significant 
deviations between the protein structures, bound ligand, 
and peptides. Molecular docking was conducted using 
the three aforementioned X-ray crystals preprocessed 
and curated (e.g., removal of water, addition of explicit 
hydrogens) using the Protein Preparation Wizard from 
the Schrodinger Suite [37, 57–60]. Missing side chains 
TC =
bc
b1 + b2 ∗ bc
.
were generated using Prime [59, 60] while the protona-
tion states of each side chain were generated using EPIK 
at pH = 7 [57, 58]. Protein minimization was performed 
using the OPLS3 force field [61–64]. Internal and external 
receptor grid boxes of 10 × 10 × 10 and 20 × 20 × 20 Å 
were defined using abacavir bound in the antigen cleft. 
The optimized structures of the test set were then docked 
with Schrodinger’s GLIDE software using both SP and XP 
scoring functions with a rigid protein, flexible ligand, and 
rigid peptide (when docked with peptide) [65–68]. Due 
to the presence of a unique peptide for each X-ray crys-
tal, we conducted the docking with and without a peptide 
covering the solvent-accessible surface of the antigen-
binding pocket. Each docking result was analyzed by 
comparing the docking and eModel scores in addition 
to the analysis of the drug’s binding mode in the B*57:01 
site. The docking score (DS) consists of a sum of the 
Glide Score, measured from the SP or XP scoring func-
tions, and the measured EPIK state penalty; the eModel 
score (eM) is a measure of the ‘favorability’ of a docked 
pose [57, 58, 65–67]. The DS may be used for comparing 
different ligands, but the eM score is suitable only to rank 
different conformations of the same ligand and should 
not be used to compare different ligands. A drug was 
considered to be B*57:01 liable (active) if the two follow-
ing empirical thresholds were met: First, the DS had to be 
at less than or equal to −7 kcal/mol and second, the eM 
score had to be less than or equal to −50 kcal/mol. These 
thresholds were previously used in virtual screening pro-
tocols for discerning micromolar binders [69–71]. How-
ever, these scoring thresholds are specific for our model 
using GLIDE docking with SP and XP scoring functions 
and are obviously subject to change depending upon the 
Table 1 Drugs used to construct test set for docking with their proposed HLA-association
a Putative; data not published
Generic name Brand name DBID Indication ADR HLA
Abacavir Zaigen DB01048 HIV antiviral Hypersensitivity B*57:01
Allopurinol Zyloprim DB00437 Uric acid inhibitor SCAR B*58:01
Atorvastatin Lipitor DB01076 High cholesterol Hypercholesterolemia cardiac heart disease DRB1*10:10a
Carbamazepine Tegretol DB00564 Seizures bipolar disorder SJS/TEN B*15:02
Ciprofloxacin Cipro DB00537 Antibiotic Gastrointestinal irritation B*50:02a
Clozapine Clozaril DB00363 Antipsychotic Agranulocytosis DRB5*02:01
Fenofibrate Tricor DB01039 High cholesterol Acute Generalized Exanthematous Pustutosis (AGEP) A*33:01a
Flucloxacillin Floxapen DB00301 Antibiotic DILI B*57:01
Methyldopa Aldomet DB00968 Anti-hypertensive N/A A*33:01a
Minocycline Minocin DB01017 Antimicrobial Thyroid hyperplasia B*35:02a
Pazopanib Votrient DB06589 Chemotherapy DILI ALT concentration increase B*57:01
Sertraline Zoloft DB01104 PTSD/OCD Serotonin syndrome A*33:01a
Simvastatin Zocor DB00641 High cholesterol Myalgia arthralgia B*13:02a
Ticlopidine Ticlid DB00208 Thrombotic stroke Agranulocytosis aplastic anemia neutropemia A*33:01
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studied protein, the software and method employed for 
the virtual screening. Our docking results were also eval-
uated using accuracy, sensitivity, specificity, positive per-
formance value (PPV), and negative performance value 
(NPV) [72]; these values can be found in Additional file 1: 
Table S1.
Results and discussion
Alignment of 3VRI, 3VRJ, and 3UPR
We began our analysis by superimposing 3VRI, 3VRJ, 
and 3UPR and we determined that the most significant 
differences between these three HLA-B*57:01 crys-
tal structures were related to the co-binding peptides. 
Indeed, when performing an all-AA residue align-
ment, 3VRI has a 96% overlay similarity with 3VRJ and 
an extremely low pairwise RMSD equal to 0.15 Å (see 
Fig. 3). Meanwhile, the all-AA residue overlay similarity 
between 3VRI and 3UPR was measured to be 76% with 
an RMSD of 0.59 Å. The major structural differences 
between 3VRI and 3VRJ from 3UPR are not related to 
the actual binding domain (chain A in 3VRI and 3VRJ 
and chains A and C in 3UPR) but rather the location of 
the interlinking chains between each crystal (chain B in 
3VRI or 3VRJ and chains B and D in 3UPR). Addition-
ally, we aligned the bound conformations of abacavir 
for all three crystals using 3VRI as the reference struc-
ture. We found that the overlay similarities were greater 
than 95% and measured RMSDs as low as 0.39 and 0.43 
Å when compared to 3VRJ and 3UPR respectively. The 
slight 3D dissimilarity between abacavir’s poses arises 
due to ring strain of the cyclopropyl group and rota-
tional variation of the hydroxyl group (as illustrated in 
Fig.  3). When a binding site alignment was performed 
(using all residues within 5 Å of abacavir), the measured 
RMSD was less than 0.4 Å for all three crystal struc-
tures, which is excellent.
The crystals 3VRI, 3VRJ, and 3UPR each con-
tained a unique co-binding peptide with sequences 
of RVAQLEQVYI (P1), LTTKLTNTNI (P2), and HSI-
TYLLPV (P3), respectively. After performing a back-
bone alignment of the peptides, it was determined that 
the three peptides have a similar binding conformation. 
When using P1 (from 3VRI) as a reference, the backbone 
alignment has been measured with an RMSD of 1.23 
and 1.78 Å with P2 (3VRJ) and P3 (3UPR) respectively, 
as shown in Fig. 4. The overlay similarities for all three 
peptides were greater than 70%. Furthermore, it can be 
noted that the three peptides have a similar length with 
both P1 and P2 including 10 amino acid residues and P3 
involving 9 residues. This high level of conformational 
similarity between the three co-binding peptides was not 
obvious because the amino acid sequence was relatively 
dissimilar (Fig. 4).
Even though these three peptides contain different 
residues, they do possess similar physical chemical attrib-
utes. For example, with the exception of P2, the ends of 
each peptide possess a basic residue and a hydrophobic 
residue (arginine and isoleucine for P1, histidine and 
valine for P3). Peptide P2 has hydrophobic residues at 
either extremities (leucine and isoleucine). Additionally, 
it should be noted that the center of each peptide con-
tains a hydrophobic residue next to a hydrophilic residue. 
Indeed, peptide P1 has a leucine next to a glutamate at 
residue positions five and six, P2 has a leucine next to a 
tyrosine for residues five and six, and P3 has a tyrosine at 
position six with both a hydrophilic threonine at position 
four and hydrophobic leucine at position six.
Fig. 3 Superimposed structures of HLA-B*57:01 protein and bound 
abacavir from crystals 3VRI (colored in red), 3VRJ (green), and 3UPR 
(blue) with measured overlay similarities and RMSD using 3VRI protein 
and abacavir as the reference structure
Fig. 4 Aligned sequences of peptides P1 (3VRI, red), P2 (3VRJ, green), 
and P3 (3UPR, blue)
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For all three peptides, the AA residues at either end 
form non-covalent interactions with the binding pocket 
to anchor the peptide into the pocket. The carbonyl 
backbone for VAL, TYR, and ILE of P1 serve as H-bond 
acceptors for the in pocket residues TRP147 and TYR84 
in addition to the formation of a salt bridge between ILE 
carboxylate group and LYS146. On the other end of P1, 
ARG serves as a H-bond donor with the pocket residues 
GLU63 and TYR171 while also forming a salt bridge 
with TYR59. Peptides P2 and P3 are anchored in a simi-
lar fashion in crystals 3VRJ and 3UPR. Importantly, the 
centroid of each peptide does not form interactions with 
binding pocket due to displacement by abacavir. The 
2D-binding modes of peptides P1, P2, and P3 are pro-
vided in Additional file 1: Fig. S1.
Furthermore, the physical binding environment of the 
binding pocket was evaluated using SiteMap [43, 44]. 
The binding pocket for each crystal was evaluated under 
three conditions: (1) abacavir was used as the reference 
ligand with peptide present, (2) abacavir was used as the 
reference ligand in the absence of a co-binding peptide, 
and (3) the co-binding peptide was used as the reference 
ligand with abacavir present. Under conditions 1 and 2, 
the measured Sscore and Dscore were ranging between 
1.1 and 1.3 indicating that the binding environment is 
extremely favorable (>0.8). Overall, condition 2 afforded 
slightly lower Sscore and Dscores, which is most likely 
due to increased solvent exposure due to the missing 
co-binding peptide. Interestingly, when the co-binding 
peptide was used as the reference ligand, the Sscore and 
Dscore were significantly lowered to a range of 0.8–1.1. 
Additionally, SiteMap identified two binding locations 
under the third condition (at either end of the peptide), 
while the center of the peptide was excluded from the 
binding surface. The observation of two binding pockets 
occurs as a result of the altered repertoire binding mech-
anism of abacavir with HLA-B*57:01: Abacavir displaced 
the center of the peptide from binding with the pocket. 
All SiteMap-generated binding surfaces are provided in 
Additional file 1: Figure S2.
Self‑docking of abacavir in 3VRI with (+) and without (−) 
the presence of a co‑binding peptide
The next step of our analysis was dedicated to the self-
docking of abacavir in both the presence and absence of 
a co-binding peptide in B*57:01. To do so, we removed 
the native pose of abacavir from 3VRI, then we re-docked 
abacavir using both Glide SP and XP scoring functions. 
This self-docking procedure was conducted in order to 
test whether molecular docking could accurately repro-
duce the native binding mode of abacavir and investigate 
the significance of the co-binding peptide. To do so, we 
aligned the highest scoring conformation of self-docked 
abacavir with the native pose of abacavir from 3VRI. Self-
docking without P1 was also performed; however, there 
is limited existing data about the potential binding mode 
of abacavir without peptide [16, 39]. When attempting 
to solve the X-ray crystals 3VRI and 3VRJ, Illing et  al. 
[16] used molecular docking to probe the binding cleft 
of HLA-B*57:01 to assist their crystallization procedure. 
Similarly, when Ostrov et  al. [39] solved for the 3UPR 
crystal, molecular docking was employed to select an 
optimized co-binding peptide for crystallization. Next, 
both the measured DS and eM scores of self-docked 
abacavir (with and without P1) were analyzed followed 
by the description of the molecular interactions between 
abacavir and HLA-B*57:01.
Surprisingly, the self-docked abacavir had a measured 
RMSD of about 1.2 Å for 3VRI with and without P1, 
regardless if the SP or XP scoring function was used. As 
illustrated in Fig.  5, this variation in RMSD was deter-
mined to be from the rotation of the hydroxyl group 
and ring strain from abacavir’s cyclopropyl group. Addi-
tional self-docking alignments were conducted for both 
3VRJ and 3UPR. The most notable difference for these 
compounds was the observance that docked abacavir 
in the absence of P2 or P3 would rotate 180° placing the 
hydroxyl group and cyclopropyl group at opposite ends 
of the binding pocket from the native crystal. However, 
when P2 or P3 were present, the predicted binding mode 
matched the native crystal. These results are provided in 
Additional file 1: Figures S3 and S4 for 3VRJ and 3UPR, 
respectively. This difference in binding orientation in the 
Fig. 5 Self-docked abacavir with measured RMSD using crystal 3VRI. 
3VRI native abacavir is shown in gray, abacavir using SP without P1 
is shown in blue, abacavir using SP with P1 is shown in red, abacavir 
using XP without P1 is shown in orange, and abacavir using XP with 
P1 is shown in green
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absence of co-binding peptide could occur from three 
possibilities: First, the X-ray crystals contain peptides 
so the actual binding mode of abacavir without peptide 
is unknown. Second, the binding pocket has similar resi-
dues allowing different orientations of abacavir to bind in 
the absence of peptide. Third, there may be two equally 
stable orientations of abacavir present in the binding 
pocket in the absence of a co-binding peptide.
 The measured DS and eM scores for self-docked 
abacavir are summarized in Table  2. For this study, a 
compound is considered as a B*57:01 binder if it affords 
a DS less than −7  kcal/mol and an eM score less than 
−50 kcal/mol [69–71]. Importantly, self-docked abacavir 
was found to be active for all three protein structures 
with and without peptides P1, P2, and P3. Furthermore, 
the DS were found to be within a 1  kcal/mol variation 
for both SP and XP scoring functions and across crys-
tal structures. Moreover, the presence of a co-binding 
peptide was found to stabilize the DS by approximately 
2  kcal/mol in all cases. We found significantly more 
variation regarding eM scores; the observed differences 
between scoring functions were ranging from 0.7 to 
4.7 kcal/mol, while the differences between crystals were 
ranging from 0.2 to 7 kcal/mol. The larger the variance in 
eM scores, the more diverse the conformational poses of 
abacavir.
Lastly, the binding modes were examined to elucidate 
the impact the co-binding endogenous peptide could 
have upon the actual DS and eM scores (DS was stabi-
lized by approximately 2  kcal/mol while the eM score 
was stabilized by 10–15 kcal/mol in the presence of pep-
tide). The binding mode of abacavir with and without P1 
generated using the SP scoring function is represented 
in Fig.  6. Figure  6a shows the binding mode of native 
abacavir with P1 (3VRI) and it was observed that the ter-
minal hydroxyl group is rotated into the binding pocket 
and undergoes H-bonding with the TYR74 residue (ROH—
TYR74 = 2.1 Å). However, when abacavir is docked without 
P1, the hydroxyl group still engages in H-bonding with a 
tyrosine residue, but it is now TYR99 (ROH—TYR99 =  2.0 
Å) as shown in Fig. 6b. However, when P1 is present, the 
hydroxyl group is rotated away from the binding pocket 
and H-bonds with the peptide backbone (carbonyl) of 
ALA3 (ROH—ALA3 = 2.0 Å) as shown in Fig. 6c. Overall, we 
determined that the H-bonding (ASH114, SER116, and 
ILE124) and π–π stacking (TRP147) between abacavir 
and the B*57:01 binding pocket involved the same amino 
acid interactions in both presence and absence of the pep-
tide except for the terminal hydroxyl group of abacavir. 
The binding modes for abacavir with 3VRJ and 3UPR are 
provided in Additional file  1: Figures  S5 and S6, respec-
tively. Thus, Glide was able to accurately reproduce the 
native binding mode of abacavir with HLA-B*57:01 and 
afforded good DS and eM scores. Performing molecular 
docking using the crystals 3VRI, 3VRJ, and 3UPR should 
thus be able to forecast meaningful interactions between 
HLA-B*57:01 and drugs from the test set. The results of 
docking using 3VRI and P1 are included in the manu-
script, while the results of docking with 3VRJ (P2) and 
3UPR (P3) are provided in the Additional file 1.
Docking a set of ADR‑causing drugs
The test set of ADR-causing drugs with known or puta-
tive HLA-binding profiles (Table  1) were docked using 
both SP and XP scoring functions. Upon inspection, we 
were able to determine that the test set of drugs used in 
this study had distinct therapeutic classes and low 2D 
chemical similarities. All of the drugs from the test set 
had distinct therapeutic classes with the exception of flu-
cloxacillin and minocycline, which were both antibacte-
rial agents. Furthermore, when the MACCS fingerprints 
[55] were calculated, the Tanimoto similarities [56] were 
quite distinct with the highest similarity (0.63) between 
the drugs atorvastatin and ciprofloxacin, and clozapine 
and ticlopidine, respectively. Abacavir and fenofibrate 
had the lowest measured structural similarity of 0.15. 
Surprisingly, the drugs abacavir, flucloxacillin, and pazo-
panib were all dissimilar with Tanimoto’s ranging from 
Table 2 DS and eM scores reported as absolute values for abacavir—B*57:01 docking with crystals 3VRI, 3VRJ, and 3UPR 
in the presence and absence of peptides P1, P2, and P3 using the SP and XP scoring functions
3VRI 3VRJ 3UPR
(−) P1 (+) P1 (−) P2 (+) P2 (−) P3 (+) P3
SP
 Docking (kcal/mol) −8.27 −10.46 −8.46 −9.64 −8.24 −9.51
 eModel (kcal/mol) −62.7 −78.5 −64.3 −79.8 −65.3 −78.3
XP
 Docking (kcal/mol) −7.99 −10.35 −7.38 −9.06 −7.77 −9.22
 eModel (kcal/mol) −58.0 −74.9 −65.0 −76.5 −62.4 −78.9
Page 9 of 17Van Den Driessche and Fourches  J Cheminform  (2017) 9:13 
0.35 to 0.40 even though these drugs are HLA-B*57:01 
liable [15, 16, 39, 53]. All pairwise Tanimoto similarities 
are provided in Additional file 1: Table S2.
Virtual screening was conducted using the three 
X-ray crystals 3VRI, 3VRJ, and 3UPR in the presence 
and absence of peptide. Herein, we reported the results 
Fig. 6 Binding mode interactions of abacavir at B*57:01 using 3VRI: a Native abacavir binding mode from X-ray crystal 3VRI with P1; b Self-docked 
abacavir using SP scoring function with P1; c Self-docked abacavir using SP scoring function without P1. B*57:01 represented as follows: Helix 
(cyan), sheet (magenta), and loops (salmon). Molecular interactions colored as follows: side chain H-bonding (dark blue), backbone H-bonding (red), 
and π–π stacking (green)
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of docking using crystal 3VRI with and without peptide 
P1 (the results pertaining to docking performed with 
3VRJ (P2) and 3UPR (P3) are provided in the Additional 
file 1). Statistical measures of our model’s ability to fore-
cast HLA-B*57:01 liable drugs have been provided in 
Additional file 1: Table S1. Interestingly, our model per-
formed very well in the absence of peptides P1, P2, and 
P3 [SEN = 0.67 (SP) and 1.00 (XP)], but when the pep-
tide was included in docking, there was a significant 
decrease in our model’s ability to predict true positives 
(SEN = 0.33 for SP and XP). However, our model’s abil-
ity to forecast true negatives was extremely good as indi-
cated by the high specificity (0.73–0.82 for SP and XP 
without peptide and 0.91–1.00 for SP and XP with pep-
tide). The accuracy, positive prediction value (PPV), and 
negative prediction value (NPV) were also measured and 
are provided in Additional file 1: Table S1.
The DS results are plotted in Fig. 7a for the entire test 
set, while eM scores are plotted in Fig.  7b. It should be 
noted, that though each score is represented in a sepa-
rate image for simplicity in viewing, the best crite-
ria for an active compound is that BOTH the DS and 
eM scoring thresholds be met (DS  ≤  −7  kcal/mol and 
eM  ≤  −50  kcal/mol, respectively) [69–71]. Using this 
dual threshold requirement, it was observed that the 
drugs abacavir, fenofibrate, and pazopanib all met the cri-
teria to be B*57:01 active drugs. The results pertaining to 
abacavir have previously been discussed in section "Self-
Docking of abacavir in 3VRI with (+) and without (-) the 
presence of a co-binding peptide". Interestingly, fenofi-
brate, a drug believed to bind the HLA-A*33:01 variant 
(Table 1), was forecasted as a HLA-B*57:01 active com-
pound by our model. This result suggests that our model 
may be inappropriately classifying fenofibrate as an HLA-
B*57:01 liable drug; however, there are instances where 
drugs have shown promiscuity towards multiple variants 
(consider carbamazepine with HLA-A*31:01 and HLA-
B*15:02) [12, 50]. As such, future studies should be per-
formed using molecular dynamics to analyze the binding 
mode and binding affinity of fenofibrate at both A*33:01 
and B*57:01 variants. Reassuringly, Glide was able to 
accurately forecast the B*57:01 active drug pazopanib 
[53]. The binding results of pazopanib are discussed in 
section "Additional focus on known HLA-B*57:01 actives: 
Flucloxacillin and Pazopanib".
Interestingly, our model identified allopurinol and clo-
zapine as two inactive compounds, i.e., failed to meet 
either DS or eM score criteria at the B*57:01 variant. 
Allopurinol is a HLA-B*58:01 active compound [48, 49] 
and was not expected to be active at the B*57:01 variant. 
Previous work had suggested that clozapine might be a 
HLA-B*39 or -B*57:01 active drug, but it was unclear 
which specific B-variant was preferred [26, 27]. In our 
current model, clozapine afforded a DS above the thresh-
old of −7  kcal/mol and an eM greater than −50  kcal/
mol providing further evidence that clozapine is not a 
B*57:01 binder. In some cases, our model produced con-
flicting results that would predict a drug as being inac-
tive or active under varying conditions. For example, 
as shown in Fig.  7a, carbamazepine afforded DS well 
below the threshold (with the exception of GXP without 
P1); however, the measured eM score of carbamazepine 
were greater than our −50 kcal/mol threshold indicating 
that carbamazepine was not an HLA-B*57:01 liable drug 
(Fig. 7b).
In other instances, the model identified a drug as 
a B*57:01 active in the absence of peptide, but when 
the P1 peptide was present in the cleft, the drug would 
fail to meet either DS, eM, or both criteria. The drugs 
atorvastatin (HLA-DRB1*10:10 active), ciprofloxacin 
Fig. 7 Docking score (a) and eModel (b) distributions for the test 
set of drugs. Scores obtained with 3VRI are reported as absolute 
values with thresholds at 7 kcal/mol (docking score) and 50 kcal/mol 
(eModel). SP results without P1 are colored in red, SP with P1 shown 
in maroon, XP without P1 shown in light blue, and XP with P1 shown 
in dark blue
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(HLA-B*50:02), and minocycline (HLA-B*35:02) were 
among these cases (Table  1). It was also observed that 
for some drugs, such as flucloxacillin, the use of SP or 
XP scoring function influenced the models prediction. 
The DS and eM scores for 3VRJ and 3UPR with the test 
set are provided in Additional file  1: Figures  S7 and S8, 
respectively.
Pearson correlation coefficients were calculated for DS 
and eM scores obtained by the three X-ray crystal dock-
ing systems (Additional file  1: Tables  S3, S4). The DS 
results without peptide showed a significant improve-
ment in fit when the XP scoring function was used 
between 3VRI, 3VRJ, and 3UPR (0.71  ≤  RSP(−)P  ≤  0.88 
and 0.92 ≤ RXP(−)P ≤ 0.98); however, when docking was 
performed in the presence of peptides P1, P2, or P3, there 
was more fluctuation in the results (0.57 ≤ RSP(+)P ≤ 0.87 
and 0.70 ≤ RXP(+)P ≤ 0.74). Interestingly, when we com-
pared eM scores, the similarity between docking grids 
appeared to be more dependent upon the scoring func-
tion employed as opposed to the influence of the pep-
tide. When the SP function was used, the crystals showed 
excellent agreement in the absence of peptide, but in the 
presence of peptide there was more variation between 
the systems (0.73  ≤  RSP(−)P  ≤  0.84 and 0.60  ≤  RSP(+)
P ≤ 0.91). Yet, when the XP function was used the over-
all fit improved in the absence and presence of peptide 
(0.60  ≤  RXP(−)P  ≤  0.91 and 0.67  ≤  RXP(+)P  ≤  0.83). For 
both DS and eM scores, the presence of peptide lowered 
the correlation, because not all of the test set drugs had a 
favorable conformation in the binding pocket with pep-
tide. The discrepancy observed between scoring func-
tions for eM correlations could result from differences 
between the SP and XP scoring functions in calculat-
ing conformational energy of the binding drug [65–68]. 
Importantly, the eM score was not used to compare 
results between different sets of ligands, but to measure 
how the SP and XP scoring functions performed when 
different crystals (3VRI, 3VRJ, and 3UPR) under differ-
ent stresses (the presence or absence of peptides P1, P2, 
and P3) were used. Essentially, this provides a baseline for 
measuring the differences between our systems.
Next, we plotted eM scores against DS in order to 
emphasize the compounds that surpassed both DS and 
eM score thresholds, as shown in Fig.  8. Interestingly, 
in the absence of P1, pazopanib is the best scoring drug 
(DSXP −9.14  kcal/mol, eMXP  =  −91.55), but when P1 
is present abacavir is the best scoring drug. One com-
pound not shown in Fig. 8 is simvastatin, which had an 
extremely favorable DS of −10.07  kcal/mol when using 
the XP scoring function with P1. However, the measured 
eM of simvastatin was highly unfavorable (eM ≥ 0 kcal/
mol). We believe this may show the limitation of Glide 
scoring functions for docking these complex tripartite 
systems. When molecular docking is performed, the 
protein is treated as a rigid system while the ligand is a 
flexible system. In this tripartite system, the co-binding 
peptide needs to be accounted for in the docking pro-
cedure. Here, the peptide is treated as a rigid system 
similarly to the protein. Clearly, molecular dynamic 
simulations will be needed in order to explore how the 
co-binding peptide adjusts to the presence of differ-
ent drugs. Furthermore, this anomaly may present evi-
dence that our model can only accurately handle ligands 
that share similar 3D-characteristics with abacavir (size, 
shape, functional groups, etc.). Future studies will incor-
porate molecular dynamics to investigate the dynamic 
relationships between the HLA-binding pocket, drug, 
and peptide.
There were two top scoring drugs when docking with 
3VRJ (see Additional file 1: Figures S9): abacavir docked 
using the SP function with peptide P2 and pazopanib 
docked using the XP function without peptide P2. When 
docking was performed with 3UPR, the top performing 
drug was again abacavir (the SP and XP scoring functions 
with peptide P3 both yielded the best DS and eM scores 
in this case). The plot of eM versus DS for 3UPR is pro-
vided in Additional file 1: Figures S10.
We should underline the results obtained in our dock-
ing study seem to be dependent on the composition of 
the co-binding peptides and this can be seen as a clear 
limitation. Thus, more analysis would be needed to study 
whether peptide P1 is rather specific to abacavir and 
therefore does not allow favorable interactions for the 
binding modes of other drugs (such as flucloxacillin or 
pazopanib which are both HLA-B*57:01 liable, but were 
predicted as inactive in the presence of peptide). Thus, 
HLA-variants may bind drugs with drug-specific (or 
Fig. 8 eModel versus docking score plot for test set of drugs. SP 
without P1 results are shown in red, SP with P1 shown as maroon, XP 
without P1 shown in light blue, and XP with P1 shown in dark blue
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class-specific) peptides that could significantly enable, 
boost, and thus impact their binding modes. Another 
possibility is related to the fact that P1 probably adopts 
a specific conformation favorable for abacavir bind-
ing. It means that other drugs may bind differently in 
the B*57:01 pocket and these binding modes are not 
favored in P1’s conformation from 3VRI. Thus molecular 
dynamic simulations [73] are needed to test and poten-
tially confirm this hypothesis at the case by case level. 
Of course, MD simulations cannot be used for screen-
ing purposes, especially considering a large collection 
of drugs (e.g., DrugBank) towards thousands of HLA 
variants. Therefore, molecular docking should still be 
considered as the main approach for high throughput 
HLA–drug screening.
Additional focus on known HLA‑B*57:01 actives: 
flucloxacillin and pazopanib
In addition to abacavir, the test set of compounds con-
tained two other drugs, flucloxacillin and pazopanib, 
known to bind HLA-B*57:01 and potentially causing 
drug-induced liver injury (DILI) [15, 53]. Glide was able 
to successfully forecast pazopanib as a B*57:01 active 
drug with DS (DSSP = −8.7 kcal/mol, DSXP = −9.2 kcal/
mol) and eM scores (eMSP  =  −78.0  kcal/mol, 
eMXP = −91.5 kcal/mol) well above the threshold in the 
absence of P1. Notably, the presence of P1 had a signifi-
cant impact upon the DS and eM scores for pazopanib. 
When the SP function was used, pazopanib’s DS sur-
passed the threshold (DSSP = −9.1  kcal/mol), while the 
eM score failed to meet it (eMSP  =  −43.2  kcal/mol). 
However, when the XP function was used the oppo-
site phenomenon was observed with the DS failing the 
threshold (DSXP = −6.6 kcal/mol) and the eM score sur-
passing it (eMXP = −56.3 kcal/mol). As a result, the bind-
ing mode of pazopanib was investigated for SP and XP 
scoring functions with and without peptide P1.
We aligned the SP and XP best docked poses and 
found that the binding modes of pazopanib were the 
same (Fig. 9a). We then found that pazopanib adopts at 
least two main conformations in the binding site. In the 
absence of P1, pazopanib favors a linear conformation 
(Fig.  9b) while in the presence of P1 a distinct struc-
tural curvature is formed (Fig. 9c). The linear conforma-
tion adopted in the absence of P1 (Fig.  9b) may occur 
as a result of optimizing ligand-residue interactions in 
the binding pocket that occur with H-bonds formed 
between TYR99 and the sulfonamide functional group, 
and ASH114 and a N-lone pair from the pyrimidine moi-
ety. Additionally, there is some π–π stacking observed 
between TYR9 and the p-methyl-m-sulfonamide-benzyl 
group as well as some stacking between TRP147 and 
the pyrimidine moiety. In the presence of P1, pazopanib 
adopts a curved conformation. There are two possible 
causes for this change in binding conformations (from 
linear to curved). First, some ligand–peptide interactions 
were not available in the absence of P1. Furthermore, the 
π–π stacking observed in the absence of P1 is no longer 
present as shown in Fig.  9c. The key peptide residues 
interacting with pazopanib are LEU5 and VAL8, which 
are H-bonding through the backbone of P1 with the 
sulfonamide functional group. There is also H-bonding 
occurring in the pocket between SER116 (not a residue of 
the peptide) and the N-lone pair from the indazole moi-
ety. Again, molecular dynamic simulations are needed to 
further investigate how the peptide influences the con-
formation of pazopanib.
The binding mode of flucloxacillin was also stud-
ied (Fig.  10). Interestingly, we found that flucloxacillin 
could adopt four different metastable conformations 
in the B*57:01 pocket and these conformations are sig-
nificantly different as indicated by the large RMSD val-
ues (Fig.  10a). We observed that in the absence of P1, 
flucloxacillin showed significant conformational varia-
tions with pairwise RMSDs greater than 8 Å regardless 
of the scoring function. However, when P1 was pre-
sent for SP and XP, the RMSD was found to be as low 
as 1.64  Å. This result indicates that the binding mode 
of flucloxacillin may be highly dependent on the co-
binding peptide. Curiously, each conformer was the 
top-scoring conformation for flucloxacillin from each 
of the conditions tested (SP with/out peptide and XP 
with/out peptide). Interestingly, the measured DS and 
eM scores from the SP scoring function were well above 
the threshold in the absence of P1 (DSSP  =  −4.5  kcal/
mol, eMSP  =  −39.6  kcal/mol) and presence of P1 
(DSSP  =  −6.3  kcal/mol, eMSP  =  −36.1  kcal/mol) indi-
cating that flucloxacillin would be inactive for B*57:01. 
However, when the XP scoring function was used, the 
DS and eM scores were significantly lower than the 
threshold in absence of P1 (DSXP  =  −8.8  kcal/mol, 
eMXP = −51.8 kcal/mol), but in the presence of P1 the 
measured DS passed our threshold while the eM score 
was greater than zero (GXP = −8.1 kcal/mol). This result 
indicates that flucloxacillin is a B*57:01 active compound 
in the absence of P1. One possible reason for this diver-
gence in the prediction results may arise from the fact 
that the XP scoring function could more accurately 
account for the flexible β-lactam subunit in flucloxacil-
lin [65–68]. Another possibility is that the ideal binding 
location of flucloxacillin is located in a different region 
of the binding pocket (as indicated by superimposition). 
These peculiar results for flucloxacillin and simvasta-
tin (XP + P1) may indicate a severe limitation of using 
molecular docking for such complicated three part sys-
tems (protein, ligand, and co-binding peptide).
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Finally, the binding mode of flucloxacillin was further 
investigated using the XP scoring function with and with-
out peptide P1 (see Fig. 10b, c). There are very significant 
differences in the binding mode indicating that the bind-
ing location in B*57:01 most likely occurs in a different 
region of the pocket than where the docking grid was 
generated using abacavir. More specifically, in the 
absence of P1, H-bonding is observed between ASH114 
and the carboxylate group and between SER116 and the 
amide linker; π–π stacking also occurs between TYR123 
Fig. 9 Binding mode of pazopanib in 3VRI. a Alignment of pazopanib from SP and XP scoring functions with and without peptide P1. SP (−) P1 is 
shown as purple, SP (+) P1 is shown as blue, XP (−) P1 is shown as green, and XP (+) P1 is shown as orange. b 2D binding mode from SP (−) P1. c 2D 
binding mode from SP (+) P1
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and the isoxazol moiety (Fig. 10b). However, when dock-
ing with P1 the ligand-residue interactions change drasti-
cally (in addition to the global orientation of the ligand). 
As shown in Fig.  10c, the H-bonding of SER116 now 
occurs with the carboxylate group, whereas π–π stacking 
occurs between TYR99 and the 2-chloro-6-fluoro-phenyl 
group. Consequently, the position of flucloxacillin has 
shifted in the protein pocket. These significant variations 
in flucloxacillin’s binding modes indicate that molecular 
dynamic studies will be needed in order to further inves-
tigate the potential binding mode(s) between B*57:01 and 
flucloxacillin.
Fig. 10 Binding mode of Flucloxacillin in 3VRI. a Alignment of flucloxacillin from SP and XP scoring functions with and without peptide P1. SP (−) 
P1 is shown as purple, SP (+) P1 is shown as blue, XP (−) P1 is shown as green, and XP (+) P1 is shown as orange. b 2D binding mode found from XP 
(−) P1. c 2D binding mode found from XP (+) P1
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Conclusions
Herein, we conducted a molecular docking study of the 
HLA-B*57:01 variant using Glide’s SP and XP scoring 
functions. We were able to self-dock abacavir, an anti-
HIV drug known to cause severe ADR via direct binding 
to B*57:01. After analyzing abacavir’s binding mode to 
B*57:01 in the presence and the absence of endogenous 
peptides, we determined that co-binding peptides play 
a significant role in the binding mode of drugs in HLA 
antigen binding cleft. Then, we docked a series of drugs 
known to trigger ADRs via direct HLA interactions and 
we found that drugs like carbamazepine, fenofibrate, 
pazopanib, and simvastatin are predicted to have some 
binding interactions with the HLA-B*57:01 variant. 
A full summary of our modeling results is provided in 
Figs.  11 and 12 for both SP and XP scoring functions 
respectively.
Reliably predicting whether a drug candidate is 
likely to be an HLA binder at a given variant consti-
tutes a potentially valuable knowledge in evaluating 
the likelihood of an associated ADR event in a sub-
population of patients. Future work will focus on the 
B*57:01 screening for the entire DrugBank database 
[74] which includes over 7000 drugs and drug candi-
dates to identify unknown drug–HLA interactions. 
Since we showed that endogenous peptides have a 
significant impact in the binding mode of drugs with 
HLA, it is still unclear how the peptide changes con-
formations in response to different drugs, and this is a 
clear limitation of molecular docking with rigid pep-
tides. Therefore, we plan to conduct peptide self- and 
cross-docking [68] in the HLA binding cleft as well as 
molecular dynamics simulations with peptides P1, P2, 
and P3 to monitor and analyze the dynamic variations 
of the binding interactions between different peptides, 
different drugs, and B*57:01. However, as demonstrated 
in this study, molecular docking represents a fast and 
reliable cheminformatics technique to forecast drug–
HLA interactions. This is critical to screen large data-
sets of chemicals towards thousands of HLA variants 
and determine whether a particular drug has a ‘best-
binding’ peptide partner that is unique given a particu-
lar HLA variant.
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